We are live on
!
Find out more
SM
Sabby Management Portfolio holdings
AUM
$45.1M
1-Year Est. Return
74.25%
This Fund
S&P 500
This Quarter
Est. Return
-21.35%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2.43B
AUM Growth
-$314M
(-11%)
Cap. Flow
-$88.1M
Cap. Flow
% of AUM
-3.63%
Top 10 Holdings %
Top 10 Hldgs %
48.1%
Holding
447
New
130
Increased
120
Reduced
90
Closed
66
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Russell 2000 ETF
IWM
|
+$38.8M |
| 2 |
Biogen
BIIB
|
+$26M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
+$23.3M |
| 4 |
Viatris
VTRS
|
+$21M |
| 5 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$16.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$28.9M |
| 2 |
Merck
MRK
|
+$17.9M |
| 3 |
ExxonMobil
XOM
|
+$14.8M |
| 4 |
ZGNX
Zogenix, Inc.
ZGNX
|
+$13.4M |
| 5 |
Lipocine
LPCN
|
+$7.13M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 13.39% |
| 2 | Energy | 1.08% |
| 3 | Technology | 0.46% |
| 4 | Materials | 0.45% |
| 5 | Consumer Discretionary | 0.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$783B
| $307M | 12.64% |
16,250
+6,250
| +63% | +$1.27M |
|
2
PUT
iShares S&P 100 ETF
OEF
$19.8B
| $273M | 11.25% |
25,500
+7,363
| +41% | +$660K |
|
3
CALL
Eli Lilly
LLY
$1.09T
| $183M | 7.54% |
21,855
-4,816
| -18% | -$407K |
|
4
CALL
Gilead Sciences
GILD
$167B
| $97.2M | 4% |
9,896
-2,981
| -23% | -$331K |
|
|
5
CALL
Biogen
BIIB
$30.4B
| $90.2M | 3.71% |
3,090
-1,255
| -29% | -$414K |
|
|
6
PUT
Gilead Sciences
GILD
$167B
| $48.8M | 2.01% |
4,973
+2,038
| +69% | +$226K |
|
|
MDCO
7
CALL
DELISTED
Medicines Co
MDCO
| $44.6M | 1.84% |
11,749
+7,314
| +165% | +$257K |
|
|
ZGNX
8
CALL
DELISTED
Zogenix, Inc.
ZGNX
| $42M | 1.73% |
31,115
+27,929
| +877% | +$504K |
|
|
9
PUT
Biogen
BIIB
$30.4B
| $41.4M | 1.71% |
1,419
+309
| +28% | +$102K |
|
10
CALL
AbbVie
ABBV
$465B
| $40.6M | 1.67% |
7,456
-559
| -7% | -$36.4K |
|
|
11
iShares Russell 2000 ETF
IWM
$80.4B
| $35.7M | 1.47% |
+327,168
| New | +$38.8M |
|
12
PUT
Edwards Lifesciences
EW
$48.2B
| $34.9M | 1.44% |
10,092
+3,090
| +44% | +$74.6K |
|
|
13
PUT
BioMarin Pharmaceuticals
BMRN
$12B
| $30.7M | 1.26% |
2,911
+1,259
| +76% | +$168K |
|
14
CALL
Tenet Healthcare
THC
$22.6B
| $28.6M | 1.18% |
+7,745
| New | +$400K |
|
|
15
CALL
BioMarin Pharmaceuticals
BMRN
$12B
| $25M | 1.03% |
2,375
-1,421
| -37% | -$190K |
|
|
GWPH
16
PUT
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $24.8M | 1.02% |
2,712
+650
| +32% | +$72.3K |
|
|
MBLY
17
PUT
DELISTED
Mobileye N.V.
MBLY
| $23.5M | 0.97% |
5,158
+1,036
| +25% | +$56.9K |
|
|
18
PUT
Viatris
VTRS
$20.8B
| $23.2M | 0.95% |
5,756
+2,500
| +77% | +$139K |
|
|
19
Biogen
BIIB
$30.4B
| $22.9M | 0.95% |
+78,629
| New | +$26M |
|
20
CALL
Sarepta Therapeutics
SRPT
$1.63B
| $21.4M | 0.88% |
6,671
-52
| -0.8% | -$1.76K |
|
|
21
PUT
Eli Lilly
LLY
$1.09T
| $20.4M | 0.84% |
2,438
+10
| +0.4% | +$844 |
|
22
PUT
State Street SPDR NYSE Technology ETF
XNTK
$2B
| $19.6M | 0.81% |
3,144
+1,816
| +137% | +$92.9K |
|
|
23
BioMarin Pharmaceuticals
BMRN
$12B
| $18.3M | 0.76% |
+174,073
| New | +$23.3M |
|
24
CALL
Bristol-Myers Squibb
BMY
$130B
| $18.2M | 0.75% |
3,073
| – | – |
|
|
ALXN
25
PUT
DELISTED
Alexion Pharmaceuticals
ALXN
| $15.2M | 0.63% |
975
+171
| +21% | +$31.2K |
|
Similar funds
CG
OC
ICCON
PCM
CAS
CM
MCMC
CTC
Sabby Management's Q3 2015 Portfolio in Review
As of Q3 2015, Sabby Management held 447 positions worth $2.43B, down 11% from $2.74B the previous quarter. Its ten largest holdings account for 48% of the portfolio.
Sabby Management withdrew a net $88.1M in Q3 2015, closing 66 positions and reducing 90 holdings. Its most notable exit was iShares 20+ Year Treasury Bond ETF, an estimated $28.9M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 13% of assets, up from 8.3% a quarter earlier, followed by Energy and Technology.
Against the trend, Sabby Management opened a new position in iShares Russell 2000 ETF worth $35.7M.
- Sabby Management's largest Q3 2015 buy was iShares Russell 2000 ETF: 327,168 shares worth $35.7M.
- Sabby Management added most to Mobileye N.V. in Q3 2015, an estimated $8.9M increase.
- Sabby Management's biggest Q3 2015 reduction was Lipocine, cutting an estimated $7.13M.
- Sabby Management fully exited iShares 20+ Year Treasury Bond ETF in Q3 2015, selling an estimated $28.9M.
- Sabby Management's ten largest holdings make up 48% of its $2.43B portfolio in Q3 2015.
- Sabby Management opened 130 new positions and closed 66 in Q3 2015.
- Sabby Management's portfolio value fell 11% quarter-over-quarter to $2.43B.
Based on Sabby Management's 13F filing for Q3 2015, filed 16 Nov 2015.